Lung Cancer. 2017 Nov;113:37-44. doi: 10.1016/j.lungcan.2017.08.021. Epub 2017 Sep 1.
EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study.
Han B1, Tjulandin S2, Hagiwara K3, Normanno N4, Wulandari L5, Laktionov K6, Hudoyo A7, He Y8, Zhang YP9, Wang MZ10, Liu CY11, Ratcliffe M12, McCormack R12, Reck M13.
MATERIALS AND METHODS:
IGNITE (non-comparative/-interventional; NCT01788163) was conducted in 90 centres (Asia-Pacific/Russia). Eligible patients: local/metastatic aNSCLC; chemotherapy-naïve, newly-diagnosed/recurrent disease after resection; ineligible for curative treatment. Patients provided a tissue/cytology (all) and a blood plasma (China/Russia/South Korea/Taiwan) sample. Primary endpoint: EGFR mutation frequency in aNSCLC patients (adenocarcinoma [ADC]/non-ADC), as per local practices.
Copyright © 2017 Elsevier B.V. All rights reserved.
Adenocarcinoma; Circulating free tumour-derived DNA; Diagnostic; Epidermal growth factor receptor; Non-small-cell lung cancer